BioNTech to Report Q3 Earnings: Is a Beat in the Cards?

Like
Comment
Favorite

BioNTech to Report Q3 Earnings: Is a Beat in the Cards?

Zacks00:10

We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell. Let’s see how things have shaped up for the quarter to be reported. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2478954406?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kDA9ni0yLcDPKdACHOlpnQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bb18a3f978dd9c6e7e344c74d8d4468e","is_english":true,"pubTime":"2024-10-26 00:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2478954406","market":"us","top_or_hot":-1,"title":"BioNTech to Report Q3 Earnings: Is a Beat in the Cards?","media":"Zacks","content":"<div>\n<p>We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell.\nLet’s see how things have shaped up for the quarter to be reported.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/biontech-report-q3-earnings-beat-161000151.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech to Report Q3 Earnings: Is a Beat in the Cards?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech to Report Q3 Earnings: Is a Beat in the Cards?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 00:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biontech-report-q3-earnings-beat-161000151.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell.\nLet’s see how things have shaped up for the quarter to be reported.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/biontech-report-q3-earnings-beat-161000151.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://finance.yahoo.com/news/biontech-report-q3-earnings-beat-161000151.html","article_id":"2478954406","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kDA9ni0yLcDPKdACHOlpnQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bb18a3f978dd9c6e7e344c74d8d4468e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478954406","pubTimestamp":1729872600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell.Let’s see how things have shaped up for the quarter to be reported.BioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer PFE. The vaccine is approved in several countries and has been a key contributor to BioNTech’s top line. The Zacks Consensus Estimate for revenues stands at $651.8 million for the third quarter.BioNTech/Pfizer’s COVID-19 vaccine sales have been declining.Revenues in the last reported quarter declined mainly due to a decrease in COVID-19 vaccine sales due to the end of the pandemic. The decline is likely to have continued in the third quarter.Also, inventory write-downs by partner PFE have been negatively impacting revenues in recent quarters.The cost of sales is expected to have continued to decline in the to-be-reported quarter.Shares of BioNTech have increased 5.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"translate_title":"BioNTech将报告第三季度收益：有望取得突破吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"PFE":0.9},"content_text":"We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell.\nLet’s see how things have shaped up for the quarter to be reported.\nFactors at Play\nBioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer PFE. The vaccine is approved in several countries and has been a key contributor to BioNTech’s top line. The Zacks Consensus Estimate for revenues stands at $651.8 million for the third quarter.\nBioNTech/Pfizer’s COVID-19 vaccine sales have been declining.\nRevenues in the last reported quarter declined mainly due to a decrease in COVID-19 vaccine sales due to the end of the pandemic. The decline is likely to have continued in the third quarter.\nAlso, inventory write-downs by partner PFE have been negatively impacting revenues in recent quarters.\nThe cost of sales is expected to have continued to decline in the to-be-reported quarter.\nAs declining COVID-19 vaccine sales continue to hurt BioNTech’s top line, investors will be keen to get an update on BNTX’s revenue guidance for 2024 on the upcoming conference call.\nShares of BioNTech have increased 5.8% year to date against the industry’s decline of 3.5%.\nImage Source: Zacks Investment Research\nBioNTech has a portfolio of pipeline candidates and multiple mRNA vaccines that are currently in early to mid-stage development, targeting various cancer indications and other infectious diseases.\nHigher costs associated with the ongoing clinical studies on these drug and vaccine candidates are likely to have escalated the research and development expenses in the to-be-reported quarter.\nBNTX's Earnings Surprise History\nBioNTech has a dismal earnings surprise history so far. The company’s earnings beat estimates in one of the trailing four quarters and missed the same on the remaining three occasions. BNTX delivered a four-quarter average earnings surprise of 18.66%. In the last reported quarter, BioNTech earnings missed estimates by 67.59%.\n\nBioNTech SE Sponsored ADR Price and EPS Surprise\n  \nBioNTech SE Sponsored ADR price-eps-surprise | BioNTech SE Sponsored ADR Quote\n\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nEarnings Whispers for BNTX\nOur proven model predicts an earnings beat for BioNTech in the to-be-reported quarter. A stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is the case here, as elaborated below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.\nEarnings ESP: BioNTech’s Earnings ESP is +10.20%. The Most Accurate Estimate stands at a loss of $1.13, while the Zacks Consensus Estimate is pegged at a loss of $1.26.\nZacks Rank: BioNTech has a Zacks Rank #3 currently. You can see the complete list of today’s Zacks #1 Rank stocks here.\nOther Stocks to Consider\nHere are some other stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.\nExelixis, Inc. EXEL has an Earnings ESP of +15.66% and a Zacks Rank #2 at present.\nShares of EXEL have gained 17.2% in the year-to-date period. Earnings of EXEL beat estimates in two of the trailing four quarters and missed the same twice, delivering an average surprise of 13.25%. EXEL will report third-quarter results on Oct. 31.\nBiogen BIIB has an Earnings ESP of +1.97% and a Zacks Rank #3.\nBiogen’s stock has lost 29% year to date. BIIB beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Biogen delivered an earnings surprise of 10.25% in the last four quarters. BIIB will report third-quarter results on Oct. 30.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nExelixis, Inc. (EXEL) : Free Stock Analysis Report\nBioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}